Unaudited Condensed Consolidated and Combined Statements of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash Flows from Operating Activities
Net income	$ 77.4	$ 70.1
Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:
Depreciation and amortization	231.1	222.3
Change in deferred income taxes	14.9	12.6
Stock-based compensation expense	36.7	20.2
Asset impairment charges	24.7	102.5
Changes in operating assets and liabilities	(267.0)	(83.4)
Other non-cash operating activities, net	(20.0)	3.5
Net Cash Provided by Operating Activities	97.8	347.8
Cash Flows from Investing Activities
Net purchases of property and equipment	(86.0)	(74.3)
Cash paid for acquisitions, net of cash acquired	(32.8)	0.0
Other investing activities, net	(41.7)	(4.6)
Net Cash Used for Investing Activities	(160.5)	(78.9)
Cash Flows from Financing Activities
Repayments of borrowings (Note 9)	(115.0)	0.0
Proceeds from issuance of long-term debt (Note 9)	0.0	2,477.7
Proceeds from issuance of common stock (Note 1)	0.0	1,659.7
Consideration paid to Lilly in connection with the Separation (Note 1)	(191.6)	(3,559.1)
Other net financing transactions with Lilly	6.3	(247.4)
Other financing activities, net	1.7	(3.7)
Net Cash Provided by (Used for) Financing Activities	(298.6)	327.2
Effect of exchange rate changes on cash and cash equivalents	4.1	15.4
Net increase (decrease) in cash, cash equivalents and restricted cash	(357.2)	611.5
Cash, cash equivalents and restricted cash at beginning of period	677.5	323.4
Cash, cash equivalents and restricted cash at end of period	320.3	934.9
Cash, cash equivalents and restricted cash at end of period	$ 677.5	$ 323.4